
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen is a leader in biotechnology-based human therapeutics, with a diverse portfolio of flagship drugs that treat a range of diseases and conditions. With a strong track record of success and a rapidly expanding pipeline, the company is well-positioned to continue its growth and transcend potential challenges such as biosimilar competition and tax litigation. Recent data on key products, such as Repatha, have shown strong growth and indicate a promising future for the company, with potential for continued success in both new and established markets.
Bears say
Amgen is facing strong competition in the biotechnology industry, with similar drugs already on the market and newer ones in the pipeline. Additionally, the company's recent acquisition of Onyx Pharmaceuticals and its rare disease drugs may not provide enough growth opportunities to offset potential competition and maintain profitability. The company's biosimilar portfolio may also face challenges in gaining market share. Positive data for its drug Tezspire in EoE is expected, but its potential may be limited compared to its competitor Dupixent. Overall, there are significant risks and uncertainties that may impact Amgen's future financial performance.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares